Every 10-Q that NUO THERAPEUTICS INC NEW (AURX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AURX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AURX filings page.
Nuo Therapeutics, Inc. develops and markets the Aurix autologous platelet-rich plasma system for chronic wound care. For the quarter ended June 30, 2026, it generated $1.77 million in revenue, up sharply from $0.70 million a year earlier, with gross profit of $1.17 million and a net loss of $0.28 million. Six‑month revenue rose to $3.07 million, and the net loss narrowed to $0.90 million from $1.40 million.
Growth was driven by higher Aurix sales, new private-label sales under the Smith+Nephew distribution agreement, and recognition of $0.16 million in distribution fee revenue. However, aggregate gross margin declined to about 66% due to low‑margin centrifuge device sales and lower margins on private‑label kits.
Liquidity remains constrained. As of June 30, 2026, cash was $0.45 million versus current liabilities of $1.55 million, notes payable totaled $1.75 million, and stockholders’ deficit was $1.54 million with an accumulated deficit of roughly $35.7 million. The company states that substantial doubt exists about its ability to continue as a going concern and is relying on secured promissory notes, bearing interest at 12% and accompanied by equity warrants, while it seeks additional capital. Management also discloses a supply interruption in a key bovine thrombin reagent and notes that although a short‑term alternative has been identified, longer‑term sourcing and regulatory solutions are still being pursued.
Nuo Therapeutics reported sharply higher Q1 2026 revenue but remains loss‑making and financially constrained. Total revenue rose to about $1.3 million, up from $0.5 million a year earlier, driven by Aurix growth and new private‑label sales plus $77,941 of Smith+Nephew distribution fee revenue.
Gross profit increased to roughly $0.85 million, though gross margin slipped to about 65% as centrifuge devices were sold at near break‑even transfer prices. Operating expenses rose to about $1.3 million, reflecting higher compensation and commissions, and the company posted a net loss of $618,466, narrower than the prior‑year loss of $746,128.
Cash was only $263,827 at March 31, 2026 against current liabilities of about $1.4 million, and stockholders’ deficit widened to approximately $1.4 million. Management states there is “substantial doubt” about the ability to continue as a going concern and is relying on external capital, including a new secured note facility of up to $1.6 million with warrants, of which $1.0 million is funded.
Nuo Therapeutics (AURX) reported Q3 2025 results showing faster top-line growth but ongoing losses and liquidity pressure. Total revenue rose to $1,032,096 from $370,951 a year ago, driven by $957,096 in product sales and $75,000 recognized from the Smith+Nephew distribution fee. Gross profit was $625,375; gross margin was 61% versus 73% last year due to low‑margin centrifuge device sales to Smith+Nephew and tariff surcharges, partly offset by fee revenue with no cost.
Operating expenses were $1,165,517, and net loss was $537,919 (basic/diluted loss per share $0.01). For the nine months, revenue reached $2,216,679 with a net loss of $1,933,736. Cash was $514,797 as of September 30, 2025, with total deferred revenue of $1,350,000 tied to the Smith+Nephew upfront distribution fee. The company raised $791,418 in a July private placement and $113,541 from option exercises. Management states substantial doubt about the ability to continue as a going concern, citing expected cash needs beyond current resources despite the new distribution agreement.